Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Accumulated Expenses (2020 - 2025)

Cresco Labs (CRLBF) has disclosed Accumulated Expenses for 5 consecutive years, with $54.3 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Accumulated Expenses fell 21.4% year-over-year to $54.3 million, compared with a TTM value of $54.3 million through Dec 2024, down 21.4%, and an annual FY2024 reading of $54.3 million, down 21.4% over the prior year.
  • Accumulated Expenses was $54.3 million for Q4 2024 at Cresco Labs, down from $69.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $130.5 million in Q4 2020 and bottomed at $54.3 million in Q4 2024.
  • Average Accumulated Expenses over 5 years is $82.9 million, with a median of $69.1 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses crashed 31.73% in 2022, then rose 6.01% in 2023.
  • Year by year, Accumulated Expenses stood at $130.5 million in 2020, then dropped by 26.85% to $95.4 million in 2021, then crashed by 31.73% to $65.2 million in 2022, then grew by 6.01% to $69.1 million in 2023, then fell by 21.4% to $54.3 million in 2024.
  • Business Quant data shows Accumulated Expenses for CRLBF at $54.3 million in Q4 2024, $69.1 million in Q4 2023, and $65.2 million in Q4 2022.